Rationale There is increasing interest in antipsychotics intended to manage positive
symptoms via D 2 receptor blockade and improve negative symptoms and cognitive deficits …

Brexpiprazole (OPC-34712, 7-{4-[4-(1-benzothiophen-4-yl) piperazin-1-yl] butoxy} quinolin-
2 (1 H)-one) is a novel drug candidate in clinical development for psychiatric disorders with …

Oral aripiprazole (Abilify®) is an atypical antipsychotic agent that is approved worldwide for
use in adult patients with schizophrenia. It is a quinolinone derivative that has a unique …

Brexpiprazole (OPC-34712, 7-{4-[4-(1-benzothiophen-4-yl) piperazin-1-yl] butoxy} quinolin-
2 (1 H)-one) is a novel serotonin-dopamine activity modulator with partial agonist activity at …

Based on the evidence that aripiprazole added to serotonin reuptake inhibitors (SRIs) or
clomipramine in treatment-resistant obsessive-compulsive disorder (OCD) has reported …

This article describes the role of a newly approved antipsychotic agent brexpiprazole in the
treatment of schizophrenia and major depressive disorder. This drug has high affinity for 5 …

There is no clear relationship between crying and depression based on human
neuropsychiatric observations. This situation originates from lack of suitable animal models …

Antipsychotic drugs are the treatment of choice in schizophrenia. Since the discovery of
chlorpromazine, several generations of antipsychotic drugs have been developed with …

Background: Recent studies revealed that bipolar disorder may be associated with deficits of
neuroplasticity. Additionally, accumulating evidence has implicated alterations of the …

Current antipsychotic drugs (APDs) act on D 2 receptors, and preclinical studies
demonstrate that repeated D 2 antagonist administration downregulates spontaneously …